Search Results

Early Results Presented From Low-Risk TAVR Study

March 5, 2018—Ron Waksman, MD, presented an interim analysis of a study assessing the safety and feasibility of transcatheter aortic valve replacement (TAVR) with commercially available valves in patients with symptomatic severe aortic stenosis who are at low risk (Society of Thoracic Surgeons score ≤ 3%) for surgical aortic valve replacement (SAVR).

Findings Published From Feasibility Study of TAVR in Low-Risk Patients

August 31, 2018—Online in Journal of the American College of Cardiology (JACC), Ron Waksman, MD, et al published findings from a prospective multicenter trial assessing the safety and feasibility of transcatheter aortic valve replacement (TAVR) with commercially available devices in low-risk patients with symptomatic severe aortic stenosis.

Thirty-Day Data From Low-Risk TAVR Trial Published and Presented

February 24, 2020—Online in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions, Ron Waksman, MD, et al published findings from a study of transcatheter aortic valve replacement (TAVR) in low-risk patients with symptomatic severe bicuspid aortic valve stenosis.

LRT Trial Evaluates TAVR in Low-Risk Patients at 1 Year

May 20, 2019—The 1-year results of transcatheter aortic valve replacement (TAVR) in the Low-Risk TAVR (LRT) trial were published by Ron Waksman, MD, et al in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions (2019;12:901–907).

Lipid-Rich Plaque Study Presented for NIRS-IVUS to Detect Patients and Plaques Vulnerable to MACE

September 24, 2018—The Cardiovascular Research Foundation (CRF) announced that results from the Lipid-Rich Plaque (LRP) study were presented by Principal Investigator Ron Waksman, MD, at TCT 2018, the 30th annual Transcatheter Cardiovascular Therapeutics scientific symposium, which is sponsored by CRF and held September 21–25 in San Diego, California.

MedStar Cardiovascular Research Network Launches Mitral Valve Screening Survey Registry

August 16, 2021—MedStar Cardiovascular Research Network announced the launch of the Mitral Valve Screening Survey (MVSS) registry.

MedAlliance’s Selution SLR Drug-Eluting Balloon Receives IDE Approval for Coronary De Novo Study

January 10, 2023—MedAlliance announced that the company’s sirolimus-eluting balloon with sustained limus release (SLR), the Selution SLR, has received conditional approval from the FDA for an investigational device exemption (IDE) to initiate a pivotal clinical trial for the device in the treatment of coronary de novo lesions.

4C Medical’s ATLAS Pivotal Trial of AltaValve TMVR System Commences Enrollment

October 14, 2024—4C Medical Technologies, Inc. recently announced it has commenced enrollment in the ATLAS pivotal trial in Europe and United States.

Study Finds That In-Stent Restenosis is Linked More to Patient Factors Than to Stent Type

December 2, 2014—Marco A. Magalhaes, MD, et al published findings from an investigation of clinical presentation of coronary in-stent restenosis (ISR) across three generations of stents. The study is available online ahead of print in Circulation: Cardiovascular Interventions.

Enrollment Phase of Genesis MedTech’s Early Feasibility Study of J-Valve Transfemoral System Concludes

February 5, 2024—Genesis MedTech announced the completed enrollment of an early feasibility study (EFS) looking at the company’s transcatheter aortic valve replacement (TAVR) system, the J-Valve transfemoral (TF) system.

Lipid-Rich Plaque Study Using Infraredx's TVC Imaging System Reaches Enrollment Milestone

April 27, 2015—Infraredx, Inc. announced the enrollment of 1,000 patients in the Lipid-Rich Plaque (LRP) study, a prospective, multicenter clinical trial designed to identify a correlation between lipid-rich plaques detected by Infraredx’s TVC Imaging System and the occurrence of a cardiac event within 2 years.

Study Shows High Stent Thrombosis Rates in African Americans

August 30, 2010—The American Heart Association announced that a study published by Sara D. Collins, MD, et al online ahead of print in Circulation showed that African American race is a distinct risk factor for developing life-threatening blood clots after receiving a drug-coated stent. African American race was the strongest predictor of clotting that occurred more than 30 days after implantation, the investigators said.

Cordis SELUTION4DeNovo DEB IDE Trial Begins Enrollment

November 6, 2023—Cordis recently announced that the first patient was enrolled in its SELUTION4DeNovo trial.